The role of dobutamine stress cardiovascular magnetic resonance in the clinical management of patients with suspected and known coronary artery disease

Table 2 Clinical data in DCMR-pos patients

	DCMR-pos patients			Patients with invasive angiography
	invasive angio	no invasive angio		stenosis*	no stenosis*
	n = 478	n = 131	p^†	n = 409	n = 69	p^‡
Clinical characteristics
Age [years]	64 ± 9	66 ± 9	0.03	64 ± 9	60 ± 10	0.001
Male, %	73	78	0.26	78	45	<0.001
Body mass index [kg/m2]	28 ± 4	27 ± 3	0.007	28 ± 4	28 ± 4	0.63
LVEF	56 ± 8	54 ± 11	0.61	55 ± 8	59 ± 6	<0.001
Hypertension, %	80	76	0.26	83	65	0.002
Hyperlipidemia, %	76	74	0.7	79	54	<0.001
Diabetes mellitus, %	29	24	0.31	30	20	0.11
Smoking, %	30	30	0.9	30	32	0.78
Family history, %	23	30	0.11	22	30	0.12
Framingham risk score	16 ± 11	18 ± 12	0.26	17 ± 11	12 ± 7	0.002
Known CAD, %	68	65	0.45	75	29	<0.001
Prior myocardial infarction, %	33	41	0.12	33	36	0.55
Prior PCI, %	58	53	0.34	64	26	<0.001
Prior CABG, %	26	27	0.9	30	6	<0.001
Medication, %
Aspirin	93	95	0.51	98	56	<0.001
Betablocker	88	89	0.68	92	58	<0.001
ACE inhibitor	70	66	0.47	72	54	0.009
Angiotensin receptor blocker	26	30	0.36	25	29	0.61
Calcium channel blocker	32	30	0.74	31	39	0.34
Statin	92	90	0.64	96	58	<0.001
Diuretic	43	41	0.8	44	37	0.37

Values are expressed as mean ± SD or %, *luminal diameter reduction ≥50% on invasive coronary angiography, ^†DCMR-pos patients with vs. without invasive coronary angiography,^‡DCMR-pos patients with vs. without coronary stenosis

ISSN: 1532-429X